NDA 022416 · Sumitomo Pharma Am
Aptiom
Eslicarbazepine Acetate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Nov 8, 2013
Approved uses
4
Original approval plus efficacy supplements
Registered trials
62
14 Phase 3, 1 recruiting
FAERS reports
3,321
2,320 serious, 98 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2023.
APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. ( 1 )
Mechanism: APTIOM is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 15, 2019 Supplement 11 · Efficacy LetterLabelMedication Guide
- Sep 13, 2017 Supplement 9 · Efficacy · priority review LabelLetterPediatric CDTL Review
- Aug 27, 2015 Supplement 1 · Efficacy LabelLetter
- Nov 8, 2013 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
4 products under this application
- APTIOM · ESLICARBAZEPINE ACETATE 600MG · TABLET, ORAL · Prescription · TE AB
- APTIOM · ESLICARBAZEPINE ACETATE 200MG · TABLET, ORAL · Prescription · TE AB
- APTIOM · ESLICARBAZEPINE ACETATE 800MG · TABLET, ORAL · Prescription · TE AB
- APTIOM · ESLICARBAZEPINE ACETATE 400MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eslicarbazepine" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset SeizuresPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01162460 · 815 participants · Start Dec 2010 · Primary completion Sep 2016
Drug: Eslicarbazepine acetate (BIA 2-093) · For: Epilepsy
Sites: S. Mamede Do Coronado, Portugal
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT00988429 · 653 participants · Start Dec 2, 2008 · Primary completion Jan 12, 2012
Drug: 800 mg QD Eslicarbazepine acetate; 1200 mg QD Eslicarbazepine acetate and 1 more · For: Partial Epilepsy
Sites: Mobile, Alabama; Northport, Alabama; Phoenix, Arizona · 162 sites in all
- Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic NeuralgiaPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT00981227 · 567 participants · Start Nov 2007 · Primary completion Jan 2009
Drug: Eslicarbazepine acetate; Placebo · For: Postherpetic Neuralgia
- Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic NeuropathyPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT00980746 · 557 participants · Start Nov 2007 · Primary completion Nov 2008
Drug: Eslicarbazepine acetate; Placebo · For: Painful Diabetic Neuropathy
- Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With FibromyalgiaPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01820585 · 528 participants · Start Apr 2009 · Primary completion Sep 2010
Drug: Placebo; ESL 400 mg and 2 more · For: Fibromyalgia
- Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With MigrainePivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01820559 · 452 participants · Start Apr 2009 · Primary completion Jun 2010
Drug: Placebo; ESL 1200 mg and 1 more · For: Migraine
- Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT00957684 · 402 participants · Start Jul 2004 · Primary completion Nov 2005
Drug: eslicarbazepine acetate; placebo · For: Refractory Partial Epilepsy
Sites: São Mamede do Coronado, Portugal
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT00957047 · 395 participants · Start Jul 2004 · Primary completion Aug 2006
Drug: eslicarbazepine acetate; placebo and 1 more · For: Partial Epilepsy
Sites: Trofa, Portugal
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure1,014
- off label use324
- drug ineffective306
- dizziness231
- somnolence193
- hyponatraemia172
- fatigue158
- headache139
- generalised tonic-clonic seizure118
- fall117
- nausea106
- therapy interrupted100
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 34 |
| 2015 | 123 |
| 2016 | 164 |
| 2017 | 247 |
| 2018 | 326 |
| 2019 | 397 |
| 2020 | 288 |
| 2021 | 397 |
| 2022 | 270 |
| 2023 | 266 |
| 2024 | 343 |
| 2025 | 267 |
| 2026 | 187 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aptiom (Eslicarbazepine Acetate)
2024 spending
$144M
Beneficiaries
8,265
83,810 claims
Per beneficiary
$17,432
$42.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $120,378,678 |
| 2021 | $124,002,820 |
| 2022 | $131,375,197 |
| 2023 | $142,014,028 |
| 2024 | $144,071,383 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
- Antiseizure Medications in Poststroke Seizures: A Systematic Review and Network Meta-Analysis.
Misra S, Wang S, Quinn TJ, et al. · Neurology 2025 · Systematic Review, Network Meta-Analysis
- Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ, Sudell M, Cividini S, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Systematic Review
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
Chang XC, Yuan H, Wang Y, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Sumitomo Pharma Am
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.